Basic Information
| LncRNA/CircRNA Name | BALR-2 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | B cell acute lymphoblastic leukemia |
| ICD-0-3 | NA |
| Methods | Microarray, qPCR etc. |
| Sample | blood (mononuclear cells) |
| Expression Pattern | up-regulated |
| Function Description | Importantly, high expression of BALR-2 correlated with poor overall survival and diminished response to prednisone treatment. BALR-2 plays a functional role in the pathogenesis and/or clinical responsiveness of B-ALL and that altering the levels of particular lncRNAs may provide a future diretcion for therapeutic development. |
| Pubmed ID | 25681502 |
| Year | 2015 |
| Title | LncRNA Expression Discriminates Karyotype and Predicts Survival in B-lymphoblastic Leukemia. |
External Links
| Links for BALR-2 | GenBank HGNC NONCODE |
| Links for B cell acute lymphoblastic leukemia | OMIM COSMIC |